Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management
Autore:
Luo, XR; Yan, AW; Liang, R; Lau, GKK;
Indirizzi:
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples RChina Univ Hong Kong Hong Kong Hong Kong Peoples R China Kong, Peoples RChina New York Presbyterian Hosp, Dept Med, New York, NY 10021 USA New York Presbyterian Hosp New York NY USA 10021 , New York, NY 10021 USA
Titolo Testata:
REVIEWS IN MEDICAL VIROLOGY
fascicolo: 5, volume: 11, anno: 2001,
pagine: 287 - 299
SICI:
1052-9276(200109/10)11:5<287:HBV(RA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; CHEMOTHERAPY-INDUCED REACTIVATION; FIBROSING CHOLESTATIC HEPATITIS; STEM-CELL TRANSPLANTATION; REPLICATION IN-VITRO; TERM FOLLOW-UP; FULMINANT-HEPATITIS; LAMIVUDINE THERAPY; LIVER-TRANSPLANTATION; FATAL REACTIVATION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
91
Recensione:
Indirizzi per estratti:
Indirizzo: Lau, GKK Univ Hong Kong, Queen Mary Hosp, Dept Med, 102 Pokfulum Rd, K1838, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong 102 Pokfulum Rd, K1838 Hong Kong Hong Kong Peoples R China
Citazione:
X.R. Luo et al., "Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management", REV MED VIR, 11(5), 2001, pp. 287-299

Abstract

In an endemic area for chronic hepatitis B infection, reactivation of thisvirus is a serious cause of morbidity and mortality in patients undergoingcytotoxic or immunosuppressive therapy. Careful prospective serological testing has shown that hepatitis B virus reactivation is a two-staged process. The initial stage occurs during intense cytotoxic or immunosuppressive therapy and is characterised by enhanced viral replication, as reflected by increases in the serum levels of hepatitis B virus DNA, hepatitis B e antigen, hepatitis B virus DNA polymerase and infection of naive hepatocytes withhepatitis B virus. The second stage is related to restoration of immune function following withdrawal of cytotoxic or immunosuppressive, therapy, which causes rapid immune-mediated destruction of infected hepatocytes. Clinically, this can lead to hepatitis, hepatic failure and even death. The occurrence and severity of hepatitis B virus reactivation after various cytotoxic or immunosuppressive therapy is unpredictable and treatment has been disappointing, largely due to the late administration of therapy. Recently, pre-emptive treatment of chronic hepatitis B patients undergoing cytotoxic or immunosuppressive therapy, with potent nucleoside analogues has shown some promising results. Further controlled studies are needed to define the incidence and risk factors of hepatitis B reactivation so that pre-emptive treatment with nucleoside analogues could be administered to those patients at high risk of disease. Copyright (C) 2001 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 12:54:00